Implementation Could Be Tough For Rebate Executive Order

On July 24, the Trump administration released three executive orders, which call for regulations allowing drugs to be imported from other countries, requiring Federally Qualified Health Centers to make insulin and epinephrine available to low-income people at the discounted prices set by the 340B Drug Pricing Program, and removing safe harbor protections under the Anti-Kickback statue for prescription drug rebates in Medicare Part D. A fourth executive order would tie drug prices to their list prices in countries with Most Favored Nation status, but it has not yet been released.

Industry experts and trade groups have been particularly critical of the executive order that directs HHS to resurrect the so-called rebate rule, which the administration withdrew in 2019.

© 2022 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today